Applications of letrozole combined with human menopausal gonadotropin in ovulation guidance intercourse and the related factors of HMG dosage

Objective To investigate the qpplication of letrozole (LE) combined with human menopausal stimulating gonadotropin (HMG) in ovulation guidance intercourse and the related factors of HMG dosage. Methods Eighty-three patients met the study criteria for the selection were selected from March 2014 to February 2015. According to whether or not with polycystic ovary syndrome (PCOS), they were divided into PCOS group (n=43) and non PCOS group (n=40). LE combined with HMG was given in the two groups. The related monitoring indicators (HMG dosage, the number of dominant follicles, ovulation, number HCG day endometrial thickness, ovulation cycle rate) and pregnancy between the two groups were compared, and the related factors of HMG osage were analyzed. Results The number of dominant follicle, ovulation number, hCG day endometrial thickness and ovulation rate had no significant differences between the two groups(P>0.05), the dosage of HMG in PCOS group was significantly higher than that in non PCOS group, the difference was significant (P 0.05). The basic follicle number and menstrual cycle were all the factors affecting the dosage of HMG, the more the basic follicle number or the menstrual cycle, the higher the HMG dose required to achieve the standard of chorionic gonadotropin. Conclusions Letrozole combined with human menopausal gonadotropin for ovulation is of great value in the guidance intercourse. In PCOS patients, the efficacy of the proposed method is comparable with that of non PCOS patients, and the menstrual cycle and the number of follicles are closely correlated with the dosage of HMG. Key words: Letrozole; Human menopausal gonadotropin; Ovulation induction; Polycystic ovary syndrome